HCL Technologies (HCL), a global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences today announced a collaboration to help life sciences companies execute and scale the next generation of digital clinical trials to reduce the time and cost of drug development.
Eli Lilly announced that Emgality (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of chronic and episodic migraine in patients with documented previous failures on two to four different standard-of-care migraine preventive medication categories, due to inadequate efficacy or for safety/tolerability reasons.
Roche has announced that its Tecentriq (atezolizumab) plus platinum-based chemotherapy has significantly reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer in the phase III IMvigor130 study.
Transgene, a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, announces that the independent Data Monitoring Committee (IDMC) of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis.
Pfizer’s rivipansel has failed to meet its primary and key secondary efficacy endpoints in phase 3 study of sickle cell disease (SCD).
Novartis said that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant could deliver a statistically significant improvement in overall survival in a phase 3 trial, called MONALEESA-3.
SpringWorks Therapeutics has secured orphan drug designation from the European Commission (EC) for its mirdametinib to treat neurofibromatosis type 1 (NF1).
Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant significantly extended life in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in a phase 3 trial.
Merck said that Keytruda in combination with chemotherapy has met one of the two primary endpoints of a phase 3 trial in triple-negative breast cancer (TNBC).
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that data from the phase III TANGO study showed that the 2-drug regimen (2DR) of Dovato (dolutegravir/lamivudine) has similar efficacy to a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs in virally supressed and stable adults with HIV-1.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.